文献速递脊柱关节炎

比美吉珠单抗治疗中轴型脊柱关节炎的疗效与安全性:两项平行3期随机对照试验结果

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
PubMed 文献 · Ann Rheum Dis · 2023-01-17

BE MOBILE 1(非放射学中轴型脊柱关节炎)和BE MOBILE 2(放射学中轴型脊柱关节炎)是双盲3期试验,评估比美吉珠单抗(新型IL-17A和IL-17F双重抑制剂)在活跃期中轴型脊柱关节炎患者中的疗效与安全性;第16周时,两项试验的主要终点ASAS40均显著优于安慰剂,且比美吉珠单抗耐受性良好。

要点

  • 第16周ASAS40:非放射学中轴型脊柱关节炎比美吉珠单抗组47.7% vs 安慰剂组21.4%,放射学中轴型脊柱关节炎比美吉珠单抗组44.8% vs 安慰剂组22.5%,均p<0.001。
  • 比美吉珠单抗在TNFi初治和TNFi应答不足患者中ASAS40应答相似。
  • 比美吉珠单抗组最常见治疗中出现的不良事件(>3%)包括鼻咽炎、上呼吸道感染、咽炎、腹泻、头痛和口腔念珠菌病;比美吉珠单抗组较安慰剂组观察到更多真菌感染(均为局部性),未报告主要不良心血管事件或活动性结核。

核心结论

  • 比美吉珠单抗通过双重抑制IL-17A和IL-17F,在非放射学中轴型脊柱关节炎和放射学中轴型脊柱关节炎患者中较安慰剂显著且快速改善疗效结局,且耐受性良好。

研究设计与样本

  • BE MOBILE 1(非放射学中轴型脊柱关节炎)和BE MOBILE 2(放射学中轴型脊柱关节炎)是双盲3期试验,平行进行52周,评估比美吉珠单抗在活跃期中轴型脊柱关节炎患者中的疗效与安全性。
  • 非放射学中轴型脊柱关节炎患者按1:1随机分配至比美吉珠单抗160 mg每4周一次组或安慰剂组,放射学中轴型脊柱关节炎患者按2:1随机分配至比美吉珠单抗160 mg每4周一次组或安慰剂组;从第16周起,所有患者均接受比美吉珠单抗160 mg每4周一次。
  • 共254例非放射学中轴型脊柱关节炎患者和332例放射学中轴型脊柱关节炎患者被随机分配。

主要发现

  • 第16周主要终点ASAS40:非放射学中轴型脊柱关节炎比美吉珠单抗组47.7% vs 安慰剂组21.4%,放射学中轴型脊柱关节炎比美吉珠单抗组44.8% vs 安慰剂组22.5%,均p<0.001。
  • 两项试验中所有排序次要终点均达到。
  • 比美吉珠单抗在TNFi初治和TNFi应答不足患者中ASAS40应答相似。
  • 观察到ASDAS状态和客观炎症指标(包括hs-CRP和骶髂关节及脊柱MRI)改善。
  • 比美吉珠单抗组最常见治疗中出现的不良事件(>3%)包括鼻咽炎、上呼吸道感染、咽炎、腹泻、头痛和口腔念珠菌病;比美吉珠单抗组较安慰剂组观察到更多真菌感染(均为局部性);未报告主要不良心血管事件或活动性结核;葡萄膜炎和裁定的炎症性肠病发生率低。

关键数值与推荐

  • 第16周ASAS40应答率:非放射学中轴型脊柱关节炎比美吉珠单抗组47.7% vs 安慰剂组21.4%,p<0.001;放射学中轴型脊柱关节炎比美吉珠单抗组44.8% vs 安慰剂组22.5%,p<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axSpA spectrum. METHODS: In parallel 52-week trials, patients with active disease were randomised 1:1 (nr-axSpA) or 2:1 (r-axSpA) to bimekizumab 160 mg every 4 weeks:placebo. From week 16, all patients received bimekizumab 160 mg every 4 weeks. Primary (Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40)) and secondary endpoints were assessed at week 16. Here, efficacy and treatment-emergent adverse events (TEAEs) are reported up to week 24. RESULTS: 254 patients with nr-axSpA and 332 with r-axSpA were randomised. At week 16, primary (ASAS40, nr-axSpA: 47.7% bimekizumab vs 21.4% placebo; r-axSpA: 44.8% vs 22.5%; p<0.001) and all ranked secondary endpoints were met in both trials. ASAS40 responses were similar across TNFi-naïve and TNFi-inadequate responder patients. Improvements were observed in Ankylosing Spondylitis Disease Activity Score (ASDAS) states and objective measures of inflammation, including high-sensitivity C-reactive protein (hs-CRP) and MRI of the sacroiliac joints and spine. Most frequent TEAEs with bimekizumab (>3%) included nasopharyngitis, upper respiratory tract infection, pharyngitis, diarrhoea, headache and oral candidiasis. More fungal infections (all localised) were observed with bimekizumab vs placebo; no major adverse cardiovascular events (MACE) or active tuberculosis were reported. Incidence of uveitis and adjudicated inflammatory bowel disease was low. CONCLUSIONS: Dual inhibition of IL-17A and IL-17F with bimekizumab resulted in significant and rapid improvements in efficacy outcomes vs placebo and was well tolerated in patients with nr-axSpA and r-axSpA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023. PMID: 36649967. doi:10.1136/ard-2022-223595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。